<DOC>
	<DOCNO>NCT00001008</DOCNO>
	<brief_summary>To determine methadone treatment affect blood level zidovudine ( AZT ) patient AIDS AIDS-related complex ( ARC ) receive oral AZT methadone therapy . In addition , blood level methadone AZT treatment study , patient receive daily oral methadone treatment evaluate sign narcotic withdrawal treatment AZT . The number death due AIDS high-risk population continue increase . Nationwide approximately 25 percent AIDS patient intravenous ( IV ) drug abuser , likely increasingly large number AIDS patient receive AZT therapy history IV drug abuse . The major chemical treatment IV drug abuse daily methadone maintenance therapy , IV drug abuser HIV positive represent large number patient undergo long-term treatment methadone AZT . Therefore , study potential drug interaction essential .</brief_summary>
	<brief_title>A Study Azidothymidine Plus Methadone Patients With AIDS AIDS Related Complex ( ARC )</brief_title>
	<detailed_description>The number death due AIDS high-risk population continue increase . Nationwide approximately 25 percent AIDS patient intravenous ( IV ) drug abuser , likely increasingly large number AIDS patient receive AZT therapy history IV drug abuse . The major chemical treatment IV drug abuse daily methadone maintenance therapy , IV drug abuser HIV positive represent large number patient undergo long-term treatment methadone AZT . Therefore , study potential drug interaction essential . The 18 patient patient AIDS ARC . Nine control patient receive methadone IV drug abuser . Nine former IV drug abuser maintain methadone least 6 month receive constant daily dose methadone least 1 month . Plasma urine level methadone determine 4 hour period . The dose AZT : For pharmacokinetic study AZT , plasma urine sample take oral dose AZT intravenous dose AZT control methadone group .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>AIDS-Related Complex</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Methadone</mesh_term>
	<criteria>Inclusion Criteria Prior Medication : Allowed : Oral nonabsorbable antifungal agent . The study include 18 patient AIDS HIVrelated symptomatic illness define CDC classification group IVa c2 . Of , 9 methadone recipient maintain methadone least 1 month receive constant daily dose 3090 mg methadone least 10 day . Nine patient former intravenous drug abuser . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Temperature &gt; 101 degree F. Ascites . Active opportunistic infection . Concurrent Medication : Excluded : Other inducer inhibitor hepatic microsomal enzyme . Any chronic systemic medication . Patients follow symptoms condition exclude : Temperature &gt; 101 degree F. Ascites . Active opportunistic infection . Prior Medication : Excluded within 72 hour study entry : All medication except oral nonabsorbable antifungal agent . Excluded within 2 week study entry : Any experimental drug . Drugs know nephrotoxic potential drug know cause neutropenia . Rifampin derivative , phenytoin , barbiturate . Active drug alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 1991</verification_date>
	<keyword>Substance Withdrawal Syndrome</keyword>
	<keyword>Methadone</keyword>
	<keyword>Opioid-Related Disorders</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Drug Interactions</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Administration , Oral</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
</DOC>